ConductScience.org, home

Trial · NCT05320523

Registered outcomes28

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
Primary
Safety of combined bilateral Globus Pallidus internus (GPi) and Nucleus Basalis of Meynert (NBM) stimulation in patients with moderate to advanced Parkinson's disease with mild cognitive impairment as determined by reported adverse events.
36 weeksSafety of combined bilateral GPi and NBM stimulation in patients with moderate to advanced Parkinson's disease having mild cognitive impairment as determined by reported adverse events.
SecondaryChange in Parkinson's Disease - Cognitive Rating Scale (PD-CRS).36 weeksThis scale can range from 0 to 134, and higher scores mean a better outcome.
SecondaryChange in Mattis Dementia Rating Scale.36 weeksThis scale can range from 0 to 144, and higher scores mean a better outcome.
SecondaryChange in Verbal Fluency Battery.36 weeksFAS and animals
SecondaryChange in Trail Making Task.36 weeksTrail Making Task Part A + B.
SecondaryChange in Stroop Test.36 weeksStroop Test (Victoria Version).
SecondaryChange in Symbol Digit Modalities Test.36 weeksDigit symbol coding - WAIS.
SecondaryChange in Parkinson's Disease Questionnaire for quality of life (PDQ-39).36 weeksThis questionnaire can range from 0 to 100%, and higher scores mean a worse outcome.
SecondaryChange in Questionnaire of the EuroQol-group (EQ-5D-5L).36 weeksThis questionnaire can range from 0 to 25, and higher scores mean a worse outcome.
SecondaryChange in Unified Parkinson's Disease Rating Scale section I (UPDRS I).36 weeksThis scale can range from 0 to 52, and higher scores mean a worse outcome.
SecondaryChange in Unified Parkinson's Disease Rating Scale section II (UPDRS II).36 weeksThis scale can range from 0 to 52, and higher scores mean a worse outcome.
SecondaryChange in Unified Parkinson's Disease Rating Scale section III (UPDRS III).36 weeksThis scale can range from 0 to 132, and higher scores mean a worse outcome.
SecondaryChange in Unified Parkinson's Disease Rating Scale section IV (UPDRS IV).36 weeksThis scale can range from 0 to 24, and higher scores mean a worse outcome.
SecondaryChange in objective assessment of gait measured by a sensor (MobilityLab) that assess step speed.36 weeks
SecondaryChange in objective assessment of gait measured by a sensor (MobilityLab) that assess number of steps per minute.36 weeks
SecondaryChange in objective assessment of gait measured by a sensor (MobilityLab) that assess distance between heels.36 weeks
SecondaryChange in objective assessment of gait measured by a sensor (MobilityLab) that assess balance.36 weeks
SecondaryChange in objective assessment of gait measured by Time Up and Go - Test 3 meters (TUG test 3M).36 weeks
SecondaryChange in objective assessment of gait measured by Time Up and Go dual task - Test 3 meters (TUG dual task - test 3M).36 weeks
SecondaryChange in objective assessment of gait measured by freezing of gait score (FOG score).36 weeks

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05320523/registered